Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
about
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewEfficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis.Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis.Enoxaparin in acute coronary syndromesPharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin.Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAnticoagulation Therapy in Patients with Chronic Kidney Disease.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.Anticoagulation in chronic kidney disease patients-the practical aspects.Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly.Low molecular weight heparin in pregnancy: current issues.Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.Venous thromboembolism prevention in acutely ill nonsurgical patients.Therapy insight: how changes in renal function with increasing age affect cardiovascular drug prescribing.Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Dosing low molecular weight heparins in kidney disease.Renal profiles of anticoagulants.Anticoagulating obese patients in the modern era.Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada.Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.How to effectively manage the event of bleeding complications when using anticoagulants.Dosing of Enoxaparin in Renal Impairment.Antithrombotic medications in dialysis patients: a double-edged sword.Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.Anticoagulation in renal failure is safe and effective.Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function.The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE).Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects.
P2860
Q26992262-C06F12AB-3E5A-46B4-AB48-78A4EC65322AQ27690235-424344F5-16EB-41AB-8368-197889A1E5CCQ27690881-4902FBB7-FC10-43BE-85A5-F2C3032E8117Q28301431-32C55761-DCB2-4684-8032-82069A79ABB0Q33362274-AFB5D533-E9F7-42FA-B706-54623D195D32Q33399576-FB287863-6F0C-4E57-A6A0-54657A165E53Q33435357-AEF2A4B6-415A-49E6-88EA-D0DADC3395B1Q35154142-754D9B5E-AE1F-4E5B-ACB5-F64B1EABC059Q35154171-E614953B-E52F-4D27-99B9-65D405EC5437Q35232128-0842EB91-4F42-4BFB-A68D-19C24D45DD89Q35825778-1FAFCA28-D570-472C-85C9-15C88869D2BEQ35826839-05C28A8D-B4C6-4D3B-A26F-917A90617DD2Q36022983-5EC10E21-135C-4417-8BEE-6F69270F3B15Q36051434-CAEABD40-9C5C-43FB-A111-65F9F22F09C8Q36128828-1346A785-095F-4B77-B15F-64EDD6F363ADQ36154876-0177681A-13EE-472C-B2CE-70C611294310Q36381972-C8A4F7AE-D7EC-491D-953A-822012AE52C7Q36603232-AB06D6EC-4695-4100-B5CC-4E22462186A5Q37454432-8DCE87E1-736E-41CA-AF57-EBEBA34E48F3Q37490581-C8099C8F-80D0-46C4-833E-18CCDBA1FFBEQ37844143-474CF6B0-B362-442A-8EB2-2F58BDA2E119Q37867276-BC402818-221A-4324-A32C-5F4BF628A5CFQ37879330-DAB2DAFC-1083-4F81-8A0B-06388CDB6F3CQ37919151-B755D8BE-C343-4811-9BAF-40DE82959030Q38000240-9F73C8BA-EBDE-475C-A439-B6F0EC450C37Q38015757-7409C6F9-4231-4AEF-A0EF-F76C97116175Q38634835-38F20EF3-BCD0-4504-8C96-8A88250D72E6Q38851458-588392D8-9E04-43BE-B235-2D3F678114AFQ38918821-BBF49571-6537-4057-A28F-B05E5F72B073Q40284785-D4D1DEBF-7396-4827-A5A8-2481F4EFE667Q41559648-C8AE5DEB-7E8C-46E8-B4E2-BB41FF84EE2DQ42690754-D4EEE917-A2E3-40C0-80A6-C8A2CC9D4690Q44557763-CFFE0E88-81D3-4A05-B0AC-FAD9C36FDC1CQ44657315-13C2F70C-CD38-4F09-A164-4BFCB510F664Q44904202-FAC5F68D-031C-47B1-8E06-32E520337011Q44921971-69760017-047E-412B-B392-977223C18B6AQ45029803-67EF0A36-25FE-449B-A1B4-AA6FE3E8D0C9Q46520643-C0CF5CC6-123A-4F83-8888-2D3C3F67D4F3Q47382989-74469952-0F60-4271-8EA9-DD5DE4140B63Q50751188-0BBEAB0F-CAF4-412F-A223-0A1F3BEB5972
P2860
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Safety and efficacy of unfract ...... ESSENCE and TIMI 11B studies.
@en
Safety and efficacy of unfract ...... ESSENCE and TIMI 11B studies.
@nl
type
label
Safety and efficacy of unfract ...... ESSENCE and TIMI 11B studies.
@en
Safety and efficacy of unfract ...... ESSENCE and TIMI 11B studies.
@nl
prefLabel
Safety and efficacy of unfract ...... ESSENCE and TIMI 11B studies.
@en
Safety and efficacy of unfract ...... ESSENCE and TIMI 11B studies.
@nl
P2093
P1476
Safety and efficacy of unfract ...... ESSENCE and TIMI 11B studies.
@en
P2093
ESSENCE and TIMI 11B Investigators
Kathleen A Stringer
Marc Cohen
Sarah A Spinler
Shaun G Goodman
Stephanie M Inverso
P356
10.1016/S0002-8703(03)00121-2
P407
P577
2003-07-01T00:00:00Z